Background Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin
analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA …

Background Despite common mechanisms of actions, glucagon-like peptide-1 receptor
agonists differ in structure, pharmacokinetic profile, and clinical effects. This head-to-head …

Background Semaglutide is an effective treatment for type 2 diabetes; however, 20–30% of
patients given semaglutide 1· 0 mg do not reach glycaemic treatment goals. We aimed to …

Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …

Background Cagrilintide, a long-acting amylin analogue, and semaglutide 2· 4 mg, a
glucagon-like peptide-1 analogue, are both being investigated as options for weight …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2· 4 mg versus semaglutide 1· 0 mg (the dose approved for …

Background Despite a broad range of pharmacological options for the treatment of type 2
diabetes, optimum glycaemic control remains challenging for many patients and new …

OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide
1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with …

Aim Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA)
indicated for glycaemic management in adults with type 2 diabetes (T2D). Oral semaglutide …

Guidelines increasingly highlight the importance of multifactorial management in type 2
diabetes, in contrast to the more traditional focus on glycemic control. Semaglutide, a …